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General methods
Galectin-1 was provided by Dr. Linda Baum and Mabel Pang of UCLA in stock aliquots of 6.4 and 7.2 mg/mL and stored at −78 °C. General reagents were purchased from Life Technologies, Inc. PAMAM dendrimers were purchased from Dendritech.
Nanoparticle formation Fluorescence microscopy
Fluorescent chromophores and fluorescent microsphere standards (FluoSpheres   ®   ) were purchased from Molecular Probes™. Fluorescent images were captured on an
Olympus BX-61 motorized microscope with MicroSuite™ software with a 100× oil immersion objective. Exposure time was optimized at 2 ms. Gimp 2.8 image manipulation software was used to combine images for subsequent particle perimeter (pixel) analysis. Pixcavator 6.0 Image Analysis software (Intelligent Perception) was used to measure particle perimeter in terms of pixel count. Particles below a threshold of 80 "round" as calculated by Pixcavator were excluded from analysis.
To a final concentration of galectin-1 of 40 µM, varying amounts of glycodendrimer (0.18, 4.5, and 13 µM; final concentration) were added to achieve the following ratios of galectin-1 to glycodendrimer: (a) 220:1; (b) 9:1; and (c) 3:1. PBS was added to bring the total volume of the solution to 100 µL. Assays were incubated for 1 hour at room temperature (19 °C). Each sample was scanned in triplicate, at intervals of approximately five minutes and vortexed between scans. The average measured S3 diameter and polydispersity of the fluorescently labeled galectin-1/glycodendrimer aggregates is provided in Table S1 . Fluorescence microscopy data was analyzed for statistically significant differences in aggregate size at the varying ratios ( Figure S1 ). For each compound, statistically significant changes in aggregate size were determined by comparing the size of aggregates formed at 220:1 to 9:1 and those formed at 9:1 to 3:1 (Table S3 ). In addition, for each compound, aggregates formed in the presence of a slight excess of galectin-1 (3:1) were analyzed for statistical significance with respect to aggregates formed in the presence of a large excess (220:1). The size of galectin-1 aggregates formed with compounds 2, 3, and 4, respectively, were compared at 220:1. Figure S1 : Average diameter (nm) of multivalent galectin-1 nanoparticles formed with multivalent glycodendrimers. Nanoparticle diameter (nm) was measured in the presence of galectin-1 at 220 molar excess, a 9 molar excess, and a 3 molar excess with compounds 2 (purple), 3 (red), and 4 (blue), respectively. Statistical analyses were performed using a paired two-tailed student's T-Test. Symbols (* and ♦) are used to indicate a statistically significant change in the size aggregates as the ratio of galectin-1 changes relative to a compound. The symbols *, **, and *** indicate a statistical significance of p < 0.05, p < 0.01, and p < 0.001, respectively, by comparing aggregates formed at 9:1 with respect to aggregates formed at 220:1, and by comparing aggregates formed at 3:1 with respect to those formed at 9:1. The symbols ♦, ♦♦, and ♦♦♦ indicate a statistical significance of p < 0.05, p < 0.01, and p < 0.001, respectively, by comparing aggregates formed at 3:1 with respect to those formed at 220:1. NS represents nonsignificant difference in aggregate size measured at 220:1 for all generations determined by ANOVA.
Pixel (count) to size (nm) calibration curve
Fluorescent microsphere standards (FluoSpheres ® , Molecular Probes™) were used to establish a calibration curve to convert the measured particle perimeter (pixels) to diameter (nm) at the optimized exposure time ( Figure S2 ). Representative images of the fluorescent microsphere standards are shown Figure S3a -c. Table S2 shows the effective diameter of the fluorescent microspheres as measured with DLS.
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Figure S2: Calibration curve correlating measured pixels to reported particle diameter (nm). 
Alexa Fluor ® 555 labeled galectin-1
For a 2 mg/mL stock solution, Alexa Fluor ® 555 NHS powder (1 mg) was dissolved in 500 mL millipore H 2 O. Galectin-1 was prepared in PBS in stock solutions of 3.6 mg/mL.
To the galectin-1 solution, Alexa Fluor ® 555 (6 equiv) was added and the reagents were allowed to react at room temperature (19 °C) for 1 h in PBS buffer. The reaction mixture was purified by dialysis using 1 kD MWCO dialysis tubing (Spectrum Laboratories, Inc., Prior to mixing the reagents, all solutions were filtered using a 0.22 µm millipore filter (Millex ® -GV 0.22 µm Syringe-Driven Filter Unit) to eliminate dust particle interference. Assays were incubated for 1 h at room temperature (19 °C). Each sample was scanned in triplicate, at intervals of approximately five minutes, and vortexed between scans. The measured effective diameter (nm), polydispersity, and signal (kcps, kilocounts per second) for each scan were averaged for 3-6 samples and reported below in Table S3 . 
Dynamic light scattering (DLS)
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Lactose inhibition
A lactose inhibition assay was performed in which monomeric lactoside was co- Table S4 . 
Controls
To galectin-1 (40 µM final concentration), mannose functionalized G(6) dendrimer (3.1 µM final concentration) was added. Aggregates of 340 ± 21 nm diameter were measured. Separate monomeric mannose and monomeric lactose inhibition experiments were performed to inhibit the galectin-1 aggregate formed with the mannose functionalized dendrimer. Additionally, to a final concentration of galectin-1 of 40 µM, polyhydroxylated G(6)-PAMAM was added, and no aggregate was detected.
(Particles of a diameter 6.8 ± 0.38 nm as measured by NNLS analysis agree with the reported value for polyhydroxylated G(6)-PAMAM dendrimer) 1 .
Solution preparation
Galectin-1 was prepared in filtered PBS. Lactose functionalized dendrimers (compounds 1, 2, 3, and 4) , mannose functionalized G(6)-PAMAM dendrimer, and a polyhydroxylated dendrimer G(6)-PAMAM were prepared by dissolving a lyophilized S10 sample in filtered Millipore water to a final concentration of 10 µM and 100 µM.
Monomeric lactoside was dissolved in filtered PBS buffer to afford a 100 µM solution.
Cell-based assays
The human prostate carcinoma cell line DU145 was purchased from ATCC ® (HTB-81™). Cellular aggregation assays were observed on a Jenco™ USA microscope with 10× objective and a Canon Powershot A630 camera at 4× magnification. All reagents for cell-based media were purchased from Gibco ® by Life Technologies™, except NaHCO 3 , which was purchased from Fisher Scientific.
Adhered cells were removed with 0.5 mM EDTA and collected in a 15 mL Falcon tube.
After sufficient centrifugation to form a cell pellet, the EDTA solution was removed and the pellet was re-suspended in 1 mL serum free media (SFM). Cells were counted using added was doubled at each stage in the assay, and SFM was added to bring the final volume to 70 µL. Table S5 below contains the volume of the reagents added for the untreated control (Tube 1), galectin-1 with increasing glycodendrimer concentrations (Tubes 2-5), and galectin-1 control (Tube 6). Assays were run in triplicate. From each Eppendorf tube, three 10 µL aliquots were spotted on a microscope slide. At 4× magnification, 4 images were taken from each spot, for a total of 36 images. 12 images were stitched together and converted to black 
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Saturation curve
A saturation curve was prepared using compound 1. To the DU145 cells (240,000 cells/70 µL) in the presence of galectin-1 (3.7 µM final concentration), 1 was added at a final concentration of 3.3 µM, 16 µM, 33 µM, and 66 µM, respectively. Representative black and white cell images are provided in Figure S8 , and the graph shown in Figure   S9 reveals a dose responsive inhibition mechanism with 1. µM galectin-1 using increasing concentrations of 1.
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Controls
A series of controls were performed to investigate the binding enhancement and the specificity of inhibition using lactose-functionalized dendrimers.
Lactose inhibition
To assess the multivalent enhancement in inhibiting cancer cell adhesion achieved with the dendrimer scaffold, a control assay was performed using monomeric lactoside.
Inhibition was observed at 6 mM monomeric lactoside ( Figure S10 ).
Figure S10: Inhibition of DU145 cellular adhesion by monomeric lactose. Inhibition of cancer cell adhesion by monomeric lactose was observed at 6 mM lactose.
Mannose-functionalized generation 6 PAMAM dendrimer
To investigate the specificity of the lactose-functionalized glycodendrimers, mannosefunctionalized generation 6 PAMAM dendrimer (4 µM and 6 µM, final concentrations) was applied to the galectin-1 DU145 system. The mannose functionalized dendrimer did not significantly impact galectin-1 mediated cellular aggregation.
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Solution preparation
Assays were run in a final volume of 70 µL. Galectin-1 was prepared at 0.5 mg/mL in PBS buffer (pH 7.4, 15 mM NaCl) from a 7.2 mg/mL stock solution. Glycodendrimer For the DU145 complete media with 10% fetal bovine serum (FBS), to SFM, 5 mL vitamin, 5 mL streptavidin/penicillin mixture, 10 mL essential amino acid, 5 mL nonessential amino acid, and 50 mL FBS were added and filled to 500 mL with SFM and sterilized using a sterile filter unit.
